Diabetes Metab J.  2014 Dec;38(6):449-455. 10.4093/dmj.2014.38.6.449.

Effectiveness of 3-Day Continuous Glucose Monitoring for Improving Glucose Control in Type 2 Diabetic Patients in Clinical Practice

• Kim SK
• Kim HJ
• Kim T
• Hur KY
• Kim SW
• Lee MK
• Min YK
• Kim KW
• Chung JH
• Kim JH

• KMID: 2174082
• DOI: http://doi.org/10.4093/dmj.2014.38.6.449

Abstract

BACKGROUND
The aim of this study was to investigate whether adjusting diabetic treatment regimens according to the information obtained from a continuous glucose monitoring system (CGMS) might lead to improved glycemic control in patients with type 2 diabetes.
METHODS
We reviewed the medical charts of 172 patients who used the CGMS for 1 year starting in December 2008 and the records of 1,500 patients who visited their regular outpatient clinics during December 2008. Of these patients, a total of 65 CGMS patients and 301 regular outpatients (control group) were enrolled in the study after propensity score matching. There were no differences in baseline glycated hemoglobin (HbA1c), age, and duration of diabetes between the CGMS and the control groups after propensity score matching. The changes in the HbA1c levels from baseline to 6 months were calculated.
RESULTS
The CGMS group showed a significant improvement in the HbA1c level compared to the control group at 3 months (7.9%+/-1.6% vs. 7.4%+/-1.2%, P=0.001) and at 6 months (7.4%+/-1.2% vs. 7.9%+/-1.6%, P=0.010). There were significant differences in the treatment modality changes between the CGMS group and the control group.
CONCLUSION
Using a 3-day CGMS was advantageous for improving glucose control in patients with type 2 diabetes and may help these patients to optimize glycemic control in clinical practice.

Keyword

Continuous glucose monitoring; Diabetes mellitus, type 2; Hemoglobin A, glycosylated

MeSH Terms

Ambulatory Care Facilities
Diabetes Mellitus, Type 2
Glucose*
Hemoglobin A, Glycosylated
Humans
Outpatients
Propensity Score
Glucose
Hemoglobin A, Glycosylated

Figure

• 

  Fig. 1 Change in the mean glycated hemoglobin (HbA1c) level in the (A) propensity score matched continuous glucose monitoring system (CGMS) and control groups, (B) propensity score matched non-insulin treated CGMS and control groups, and (C) propensity score matched insulin-treated CGMS and control groups. Values are presented as mean±standard deviation. aP<0.05 vs. control at 3 months, bP<0.05 vs. control at 6 months.

Reference

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577–1589.

2. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006; 295:1681–1687.

3. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005; 54:1–7.

4. Varanauskiene E. Can blood glucose self-monitoring improve treatment outcomes in type 2 diabetes? Diabetes Res Clin Pract. 2008; 82:Suppl 2. S112–S117.

5. Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, Holman R, Kinmonth AL, Neil A. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ. 2007; 335:132.

6. Farmer AJ, Wade AN, French DP, Simon J, Yudkin P, Gray A, Craven A, Goyder L, Holman RR, Mant D, Kinmonth AL, Neil HA. DiGEM Trial Group. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Health Technol Assess. 2009; 13:iii–iiv. ix–xi. 1–50.

7. Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JH, White NH, Mastrototaro JJ. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther. 2000; 2:49–56.

8. Lagarde WH, Barrows FP, Davenport ML, Kang M, Guess HA, Calikoglu AS. Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized, controlled trial. Pediatr Diabetes. 2006; 7:159–164.

9. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003; 111(5 Pt 1):933–938.

10. Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, Tobian J, Gross T, Mastrototaro J. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004; 79:1521–1526.

11. Yates K, Hasnat Milton A, Dear K, Ambler G. Continuous glucose monitoring-guided insulin adjustment in children and adolescents on near-physiological insulin regimens: a randomized controlled trial. Diabetes Care. 2006; 29:1512–1517.

12. Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, Garg SK. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics. 2001; 107:222–226.

13. Funnell MM, Brown TL, Childs BP, Haas LB, Hosey GM, Jensen B, Maryniuk M, Peyrot M, Piette JD, Reader D, Siminerio LM, Weinger K, Weiss MA. National standards for diabetes self-management education. Diabetes Care. 2010; 33:Suppl 1. S89–S96.

14. Juvenile Diabetes, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008; 359:1464–1476.

15. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther. 2009; 11:Suppl 1. S55–S67.

16. Cooke D, Hurel SJ, Casbard A, Steed L, Walker S, Meredith S, Nunn AJ, Manca A, Sculpher M, Barnard M, Kerr D, Weaver JU, Ahlquist J, Newman SP. Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA(1c) in insulin-treated diabetes (MITRE Study). Diabet Med. 2009; 26:540–547.

17. Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care. 2003; 26:1153–1157.

18. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care. 2001; 24:1858–1862.

19. Karter AJ, Ferrara A, Darbinian JA, Ackerson LM, Selby JV. Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diabetes Care. 2000; 23:477–483.